Literature DB >> 26177728

The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.

Akinao Okamoto1, Masamitsu Yanada1, Yoko Inaguma1, Masutaka Tokuda1, Satoko Morishima1, Tadaharu Kanie1, Yukiya Yamamoto1, Shuichi Mizuta1, Yoshiki Akatsuka1, Tetsushi Yoshikawa2, Yoshikazu Mizoguchi3, Shigeo Nakamura4, Masataka Okamoto1, Nobuhiko Emi1.   

Abstract

Epstein-Barr virus (EBV)-encoded small RNA in situ hybridization (EBER-ISH) is a widely accepted method to evaluate EBV involvement in diffuse large B-cell lymphoma (DLBCL), although little is known regarding associations between EBV DNA load and the EBER status and whether EBV DNA load data provide additional clinical information. In this study, we quantified EBV DNA load in diagnostic specimens from DLBCL patients diagnosed at our hospital to evaluate clinical implications of EBV DNA load in diagnostic specimens as contrasted with EBER-ISH. Among 140 DLBCL patients without underlying immunodeficiency, 51 were evaluable for both EBER and EBV DNA load, 83 for EBER only and one for EBV DNA load only. The median EBV DNA load was 708 copies/µg. Although EBV DNA load was significantly higher for EBER-positive patients than for EBER-negative patients (p < 0.001), EBV DNA was detected in up to 72% of EBER-negative patients. Progression-free survival and overall survival were significantly worse for patients with EBV DNA load above 700 copies/µg than for those with EBV DNA load below 700 copies/µg (p = 0.009 and p = 0.003); they were also significantly worse for EBER-positive patients than for EBER-negative patients (p < 0.001 and p = 0.001). Even among EBER-negative patients, higher EBV DNA load conferred worse progression-free survival and overall survival (p = 0.041 and p = 0.013). These findings indicate that EBV DNA load in diagnostic specimens is not a simple surrogate for the EBER status and may be a potential biomarker associated with EBV involvement and prognosis in DLBCL.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  EBER; EBV; EBV DNA load; Epstein-Barr virus; diffuse large B-cell lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26177728     DOI: 10.1002/hon.2245

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  11 in total

Review 1.  Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

Authors:  Christopher Melani; Elaine S Jaffe; Wyndham H Wilson
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

2.  High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.

Authors:  Hajime Senjo; Kenji Hirata; Koh Izumiyama; Koichiro Minauchi; Eriko Tsukamoto; Kazuo Itoh; Minoru Kanaya; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Journal:  Blood Adv       Date:  2020-05-26

3.  Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.

Authors:  Xiaojuan Gao; Jia Li; Yaqi Wang; Shuai Liu; Baohong Yue
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

Review 4.  Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update.

Authors:  Maria K Smatti; Duaa W Al-Sadeq; Nadima H Ali; Gianfranco Pintus; Haissam Abou-Saleh; Gheyath K Nasrallah
Journal:  Front Oncol       Date:  2018-06-13       Impact factor: 6.244

5.  Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.

Authors:  Hajime Senjo; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Kenji Hirata; Akio Mori; Makoto Saito; Masanori Tanaka; Hiroaki Iijima; Eriko Tsukamoto; Kazuo Itoh; Shuichi Ota; Masanobu Morioka; Daigo Hashimoto; Takanori Teshima
Journal:  Cancer Med       Date:  2019-02-20       Impact factor: 4.452

Review 6.  Estimating the global burden of Epstein-Barr virus-related cancers.

Authors:  Yide Wong; Michael T Meehan; Scott R Burrows; Denise L Doolan; John J Miles
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-27       Impact factor: 4.553

7.  CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

Authors:  Chen-Xing Zhao; Zi-Xun Yan; Jing-Jing Wen; Di Fu; Peng-Peng Xu; Li Wang; Shu Cheng; Jian-da Hu; Wei-Li Zhao
Journal:  Mol Cancer       Date:  2021-12-01       Impact factor: 27.401

Review 8.  New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-11-19       Impact factor: 0.196

9.  High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.

Authors:  Nathan D Montgomery; Cara Randall; Matthew Painschab; Ryan Seguin; Bongani Kaimila; Edwards Kasonkanji; Takondwa Zuze; Robert Krysiak; Marcia K Sanders; Avian Elliott; Melissa B Miller; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Blossom Damania; Tamiwe Tomoka; Yuri Fedoriw; Dirk P Dittmer; Satish Gopal
Journal:  Cancer Med       Date:  2019-11-29       Impact factor: 4.452

Review 10.  Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma.

Authors:  Paola Chabay
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.